News Apitope announces IPO to fund MS drug development Biotech Apitope plans to float on the Brussels stock exchange to raise funds to develop a potential new MS drug.
News Apitope aims to bounce back from MS setback Biotech looks for funding and long-term development partner
News Apitope to develop MS drug, Merck KGaA tie-up ends Anglo-Belgian biotech will continue clinical development.
Oncology Treating primary bone cancer: The potential of listeria-base... In a new pharmaphorum podcast, Paul Romness, president and CEO of OS Therapies, discusses the company's work in osteosarcoma.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face